Syros Pharmaceuticals, Inc. (SYRS) financial statements (2021 and earlier)

Company profile

Business Address 35 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:911007284
Cash and cash equivalents41503259
Short-term investments50504025
Other undisclosed cash, cash equivalents, and short-term investments(0)0  
Restricted cash and investments010 
Receivables   1
Other undisclosed current assets23111
Total current assets:1151027386
Noncurrent Assets
Finance lease, right-of-use asset1
Operating lease, right-of-use asset16
Property, plant and equipment15445
Restricted cash and investments3000
Other noncurrent assets0110
Total noncurrent assets:35556
TOTAL ASSETS:1501077891
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11765
Accounts payable6322
Accrued liabilities1111
Employee-related liabilities4322
Deferred revenue6
Debt1000
Deferred compensation liability   0
Deferred revenue and credits 1
Contract with customer, liability2
Other undisclosed current liabilities61164
Total current liabilities:24201210
Noncurrent Liabilities
Long-term debt and lease obligation24000
Capital lease obligations000
Operating lease, liability24
Liabilities, other than long-term debt23811
Deferred revenue and credits11
Deferred revenue23
Contract with customer, liability8
Total noncurrent liabilities:47811
Total liabilities:70281311
Stockholders' equity
Stockholders' equity attributable to parent79796581
Common stock0000
Additional paid in capital372296221182
Accumulated other comprehensive income (loss)0(0)(0)(0)
Accumulated deficit(293)(218)(155)(101)
Total stockholders' equity:79796581
Other undisclosed liabilities and equity10  
TOTAL LIABILITIES AND EQUITY:1501077891

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net10
Gross profit:2210
Operating expenses(80)(66)(56)(48)
Operating loss:(78)(64)(55)(48)
Nonoperating income
(Other Nonoperating income)
2210
Interest and debt expense(0)   
Loss from continuing operations before income taxes:(76)(62)(54)(48)
Income tax expense(0)(0)  
Loss before gain (loss) on sale of properties:(76)(62)(54)(48)
Other undisclosed net income00  
Net loss attributable to parent:(75)(62)(54)(48)
Preferred stock dividends and other adjustments   (4)
Net loss available to common stockholders, diluted:(75)(62)(54)(51)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(75)(62)(54)(48)
Other comprehensive loss   (48)
Comprehensive loss:(75)(62)(54)(95)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0) 
Comprehensive loss, net of tax, attributable to parent:(75)(62)(54)(95)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: